

JPMA Charter of Corporate Behavior

Established on November 19, 1997

Revised on November 17, 2004

Revised on March 16, 2011

Revised on October 18, 2018

Revision of the JPMA Charter of Corporate Behavior

The mission of pharmaceutical companies is to contribute to the improvement of the well-being and medical care of the people in the world through the continuous development and the provision of stable supply of excellent medicines and contribute to the realization of healthy and high-quality lifestyles. To attain this end, pharmaceutical companies are expected to sincerely and exhaustively pursue advances in the life sciences and engage in business activities based on the highest ethical standards.

In 1993, the Japan Pharmaceutical Manufacturers Association (“JPMA”) established the JPMA Promotion Code for Prescription Drugs and in 1997 also established the JPMA Charter of Corporate Behavior (the “Charter”).

Thereafter, in order to meet the emerging expectations and changes in society, JPMA has voluntarily advanced standards for business ethics and legal compliance among member companies through the establishment of Compliance Program Guidelines in 2001 (the “Guidelines”) and revisions of the Charter and the Guidelines in 2004 and 2011.

At a global level, companies, as members of the society, have been requested to engage in activities to address social issues and problems and in 2015 the United Nations adopted the “Sustainable Development Goals” (SDGs) as the unified target for realization of a sustainable society. Under such circumstances, at the country level, the Japan Federation of Economic Organizations revised its “Charter of Corporate Behavior” in November 2017 for the implementation of SDGs through the realization of a future society or Society 5.0 (Note), in which people’s lives and the entire society will be optimized by actively maximizing the use of innovative technology.

JPMA has recently revised the Charter with the belief that member companies shall pursue business activities in full consideration to the environment, society and governance (ESG) and thereby contribute to the realization of a sustainable society as well as the member companies’ own mission as pharmaceutical companies.

All of the JPMA member companies hereby commit that they will fully recognize their missions as pharmaceutical companies, respect the spirit of the Charter, and embrace and realize such a spirit on their own volition. In addition, the member companies will address their social responsibilities by urging their own companies as well as group companies and other companies within their supply chains to promote innovative changes in their business activities.

Note: Society 5.0 means the fifth and the newest society emerging after the hunting society, agrarian society, industrial society and information society in the history of development of human society.

JPMA Charter of Corporate Behavior

The mission of pharmaceutical companies is to contribute to the improvement of the health and well-being of the people in the world through the continuous development and provide stable supply of excellent medicines. The companies shall undertake important roles in the promotion of “patient participatory medicine” and contribute to the realization of a sustainable society.

To attain this end, JPMA member companies shall, based upon the principles of behavior hereunder, observe the provisions and the spirit of laws, rules and regulations throughout the world and fulfill their social responsibilities based on the highest ethical standards.

(Sustainable Economic Growth and Resolution of Social Issues)

1. The member companies engage in research and development activities for innovative new drugs that contribute to health care, and provide stable supply of effective, safe, high-quality medicines as quickly as possible. At the same time, as companies involved in an industry that is instrumental to the creation of innovation, contribute to the growth and efficiency of the national economy through the development of safe, high-quality medicines that meet health care needs.

(Scientific and Accurate Research and Development)

2. The member companies conduct, in cooperation with medical institutions, scientifically accurate clinical trials with full respect of the human rights of research subjects and careful consideration to ensure their safety. The member companies conduct necessary experiments on animals as non-clinical trials, taking the welfare of animals into full consideration. The member companies properly handle data pursuant to relevant laws and regulations, internal rules, and scientific appropriateness when applying for the manufacture and sale of medicines.

(Promotion of Appropriate Use and Utilization of Medicines)

3. The member companies accurately provide domestic and overseas scientifically verified information relating to quality, safety, and effectiveness of medicines so as to ensure appropriate use and utilization of medicines, and gather, analyze and evaluate information after manufacture and marketing, and promptly disseminate such information.

(Relationships of Mutual Trust with Healthcare Professionals and Patients)

4. The member companies have good and faithful communication with healthcare professionals and patients to gain their satisfaction and trust.

(Fair Business Practices)

5. The member companies engage in trading and distribution appropriate for medicines, as product related to life science, through fair and free competition as well as responsible procurement. The companies also maintain sound relationships with healthcare professionals, political bodies and government agencies.

(Strict Control of Information)

6. With rapid growth in IT evolution and use, the member companies pay close and reasonable attention to the protection of personal information and customer information and extend full preparation for the strict control of information.

(Fair Disclosure of Information, Constructive dialogue with Stakeholders)

7. For enhancement of corporate value, the member companies disclose corporate information in a timely manner, appropriately and fairly and dialogue constructively with stakeholders surrounding pharmaceutical companies.

(Engagement in Environmental Issues)

8. The member companies proactively initiate measures in acknowledgment of environmental issues, the common challenges they pose to humanity and their importance to a corporation's operation and persistence.

(Reform of Work Practices and Enhancement of Workplace Environments)

9. The member companies realize work-life balance in respect of the diversity, character and individual personalities of employees and provide a comfortable, safe, and great-place-to-work environment and thereby enhance employees' ethics and qualifications.

(Involvement in community and contribution to its development)

10. The member companies actively engage in community involvement activities and contribute to community development as a good corporate citizen.

(Thorough Crisis Management)

11. The member companies conduct thorough and organized crisis management in the face of actions by antisocial forces, terrorism, cyberattacks, natural disasters, pandemics and other crises that pose a threat to civil society and corporate activity.

(Respect for Human Rights)

12. The member companies conduct business that respects the human rights of all persons.

(Role of Top management and implementation of this Charter)

13. Respective managements of the member companies recognize that it is their role to realize the spirit of this Charter and take the lead in an exemplary manner to implement the Charter within the company and its entire corporate group, while encouraging their business partners to do so in the same manner. Furthermore, the management shall always try to keep abreast of what people inside and outside their company say and think about, and set up effective mechanisms for successful governance in order to implement the Charter.

In the event that the corporation violates the spirit of this Charter and loses the trust of society, the management shall proactively take responsibility to respond to the situation, including resolving the problem, investigating the causes, and preventing the problem from recurring and rebuild credibility and trust.